A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease

Key facts

Sponsor

BioMarin Pharmaceutical

Principal Investigator

Jessica Cohen Pfeffer, MD

Medical Monitor

Intervention

BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)(drug)

Eligibility

2 years · All sexes

Study locations (5)

• Orange, California, United States
• Columbus, Ohio, United States
• Hamburg, Germany
• Rome, Italy
• London, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for CLN2 disease

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT05791864
  A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease
  Tern Therapeutics, LLC
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05152914
  Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2
  David L Rogers, MD

See all trials for CLN2 disease →